Jefferies lowered the firm’s price target on Sutro Biopharma (STRO) to $4 from $7 and keeps a Buy rating on the shares. After having caught up with management, the firm updated its operating expense estimates based on early pipeline expectations, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers
- Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo
- Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase
- Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results
- Sutro Biopharma enters research collaboration with FDA for ADC standards